A recent study suggests that people who discontinue blockbuster weight-loss injections like Mounjaro or Wegovy can put back on shed pounds far faster than those who halt conventional diet and exercise plans.
Findings released in a prominent medical journal demonstrates that while obese people often shed a large proportion of their body weight while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month after stopping.
"Users using such drugs must be aware of the danger of quick rebound weight gain when the therapy concludes," warns lead investigator Dr. Susan Jebb.
That rate of regain implies a return to original mass within about a year and a half.
Analyzing Treatments
The study, which looked at dozens of studies involving thousands of participants, compared the effects of GLP-1 agonists with older methods.
Researchers emphasize that people who lose weight through lifestyle changes alone generally see a more gradual weight regain—around 100 grams monthly—post-intervention.
Explaining the Quick Regain
Nutrition scientists propose the mechanism of the injections is key to understanding the amplified regain.
GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates hunger.
"Artificially providing the hormone concentrations several times higher than the body's typical production might result in the system to produce less of its own natural hormone, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this hormone supplement means hunger is no longer kept in check, making excessive eating a significant risk."
An Ongoing Disease?
Medical guidelines recommend the jabs for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
A number of clinicians say that, due to the likelihood of weight regain, the treatment is often life-long.
This perspective is echoed by pharmaceutical companies, who note that the findings "underscore the persistent character of excess weight," comparing it to managing conditions like diabetes.
Patient Experiences
People who have stopped the jabs explain a sudden return of appetite.
"I experienced a switch that goes on and you become ravenous," said a patient.
This difficulty is compounded if users have not established permanent lifestyle or habit modifications during treatment.
Significant Adoption
Recent estimates suggest that millions of people in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Use is more common among women compared to men.
- The middle-aged age group shows the highest usage rates.
- Many obtain the medications through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are powerful tools for shedding pounds, they are not a permanent fix and lasting health benefits hinges on integrated lifestyle support.
